Phase II study of carboplatin (CBDCA) in refractory multiple myeloma. A Southwest Oncology Group study.
Nineteen patients with multiple myeloma resistant to standard alkylating agent therapy or to the VAD regimen received carboplatin at a planned daily dose of 100 mg/M2 on four successive days. Two patients erroneously received a four-fold higher drug dose resulting in bone marrow aplasia and death without antitumor effect in one patient with post-mortem examination. No anti-tumor effect was observed among 15 patients evaluable for response (two lacked follow-up examination of tumor markers). Major toxicities were hematologic and included grade > or = III, leukopenia in 9, thrombocytopenia in 6 and anemia in 3 of the 17 evaluable patients. Their median survival was 9 months. These results indicate that carboplatin is inactive in refractory multiple myeloma.
Barlogie
B
B
University of Arkansas for Medical Science, Little Rock.
Crowley
J
J
Salmon
S E
SE
Bonnet
J
J
Weick
J K
JK
Hayden
K
K
D000328:Adult; D000368:Aged; D000740:Anemia / Q000139:chemically induced; D016190:Carboplatin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000401:mortality; D015996:Survival Rate; D013921:Thrombocytopenia / Q000139:chemically induced
D016190:Carboplatin